Holders over time
Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
- IBRX
- ARGX
| Quarter | IBRX | ARGX |
|---|---|---|
| Q3 2020 | none listed holders, n.a. | 8 holders, $3.6bn |
| Q4 2020 | none listed holders, n.a. | 7 holders, $4.1bn |
| Q1 2021 | none listed holders, n.a. | 8 holders, $4.1bn |
| Q2 2021 | none listed holders, n.a. | 9 holders, $4.6bn |
| Q3 2021 | none listed holders, n.a. | 8 holders, $4.5bn |
| Q4 2021 | none listed holders, n.a. | 9 holders, $5.3bn |
| Q1 2022 | none listed holders, n.a. | 8 holders, $5.3bn |
| Q2 2022 | none listed holders, n.a. | 13 holders, $6.5bn |
| Q3 2022 | none listed holders, n.a. | 14 holders, $5.3bn |
| Q4 2022 | none listed holders, n.a. | 13 holders, $5.5bn |
| Q1 2023 | none listed holders, n.a. | 13 holders, $5.9bn |
| Q2 2023 | none listed holders, n.a. | 18 holders, $6.6bn |
| Q3 2023 | none listed holders, n.a. | 21 holders, $8.7bn |
| Q4 2023 | none listed holders, n.a. | 17 holders, $6.3bn |
| Q1 2024 | none listed holders, n.a. | 13 holders, $6.8bn |
| Q2 2024 | 1 holders, $2.8m | 14 holders, $7.9bn |
| Q3 2024 | 1 holders, $1.6m | 13 holders, $10.7bn |
| Q4 2024 | 1 holders, $8.8m | 14 holders, $12.3bn |
| Q1 2025 | 2 holders, $11m | 17 holders, $11.8bn |
| Q2 2025 | 1 holders, $9.1m | 18 holders, $10.8bn |
| Q3 2025 | 1 holders, $13m | 16 holders, $13.8bn |
| Q4 2025 | none listed holders, n.a. | 16 holders, $14.8bn |
| Q1 2026 | 3 holders, $145m | 11 holders, $12.3bn |
| Q2 2026 | 4 holders, $235m | 14 holders, $15.0bn |
IBRX
Immunitybio Inc
- Holders
- 4
- Reported value
- $235m
- Buyers
- 13
- Sellers
- 11
Breadth +2 among 91 comparable managers.
ARGX
Argenx Se
- Holders
- 14
- Reported value
- $15.0bn
- Buyers
- 16
- Sellers
- 15
Breadth +1 among 91 comparable managers.
Who holds both, Q2 2026
Among the 15 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.
Only IBRX (1)
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.